DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Ho...(our current pipeline of transplant/oncol...),Health

"We are very pleased to begin this partnership with Sigma-Tau," said Christopher J. Schaber, PhD, President and CEO of DOR. "Sigma-Tau's premium investment in DOR shares gives us the cash necessary to complete our upcoming confirmatory Phase 3 clinical trial of orBec(R) in GI GVHD. This partnership will also provide for the launch and commercialization of orBec(R) in North America, without any further related expense to DOR or its shareholders. It also provides us with the potential for ongoing development funding across multiple indications for orBec(R) and oral BDP."

Dr. Schaber continued, "We have known Sigma-Tau for a long time, as they have been an investor in DOR for several years. We are confident in their strong commitment to working with other biotech companies, and recognize their expertise in commercializing orphan products. We welcome them to our Board of Directors. Together with Sigma-Tau, we are optimistic about the prospects for our orBec(R) and Oral BDP pipelines and look forward to the possibility of having these products approved by the FDA."

About orBec(R) and Oral BDP

Two prior randomized, double-blind, placebo-controlled Phase 2 and 3 clinical trials support orBec's(R) ability to provide clinically meaningful outcomes when compared with the current standard of care, including a lowered exposure to systemic corticosteroids following allogeneic transplantation. Currently, there are no approved products to treat GI GVHD. The first trial was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center. The second trial was a 129-patient pivotal Phase 3 multi-center clinical trial of orBec(R) conducted at 16 leading bone marrow/stem cell t
'/>"/>